Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Bicycle Therapeutics PLC as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- +11 vs. Q3 2025
- Shares held
- 39.2M
- +2.37M (+6.4%) vs. Q3 2025
- Total value
- $276.9M
- −$7.96M (−2.8%) vs. Q3 2025
- New holders
- 22
- 35 more added
- Sold out
- 11
- 29 more reduced
1 institution that held it in Q3 2025 haven't filed for Q4 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| GSK plc | 1,529,561 | $10.8M | 1.36% | +1,529,561 | New |
| Long Focus Capital Management, LLC | 1,633,091 | $11.6M | 0.58% | +214,396+15.1% | Added |
| Acadian Asset Management LLC | 1,671,258 | $11.8M | 0.02% | +356,702+27.1% | Added |
| Siren, L.L.C. | 2,012,752 | $14.3M | 0.43% | 00.0% | Unchanged |
| Westfield Capital Management Co LP | 3,016,026 | $21.4M | 0.09% | +63,483+2.2% | Added |
| Armistice Capital, LLC | 3,236,000 | $22.9M | 0.56% | +258,000+8.7% | Added |
| FCPM III Services B.V. | 3,468,430 | $24.6M | 3.22% | +16,100+0.5% | Added |
| Baker Bros. Advisors LP | 10,885,357 | $77.1M | 0.45% | 00.0% | Unchanged |
| DekaBank Deutsche Girozentrale | 30,000 | – | – | 00.0% | Unchanged |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −27,959−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −14,972−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −13,259−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −12,375−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −630−100.0% | Sold out |
| Manchester Capital Management LLC | 0 | $0 | 0.00% | −590−100.0% | Sold out |
| Toth Financial Advisory Corp | 0 | $0 | 0.00% | −150−100.0% | Sold out |
| Principal Securities, Inc. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | – | – | – | – | Not filed |